Letermovir 480 mg once daily
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Kidney Transplant; Complications
Conditions
Kidney Transplant; Complications, CMV
Trial Timeline
Sep 25, 2023 → Sep 1, 2026
NCT ID
NCT06001320About Letermovir 480 mg once daily
Letermovir 480 mg once daily is a phase 3 stage product being developed by Merck for Kidney Transplant; Complications. The current trial status is active. This product is registered under clinical trial identifier NCT06001320. Target conditions include Kidney Transplant; Complications, CMV.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06001320 | Phase 3 | Active |
Competing Products
20 competing products in Kidney Transplant; Complications